Study MJP2 protocol was initially submitted on March 9, 2021. The study was put on hold by FDA on May 10, 2021 with additional comments for the hold provided on June 3, 2021. MAPS provided FDA with a response …
On April 15, 2022, MAPS wrote the second progress report for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). The first report was for the reporting period ending January 15, 2022. Read the …
Highlights A randomized, placebo-controlled, Phase 3 trial demonstrated the safety and efficacy of MDMA-assisted therapy for the treatment of severe posttraumatic stress disorder (PTSD) Participants met …
On January 14, 2022, MAPS released the first MRA VMR Grant Update for the reporting period ending January 15, 2022 for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). The quarterly performance …
MAPS) has been awarded a $12,979,050 grant from Michigan’s $20 million competitive 2021 Veteran Marijuana Research Grant Program. The program, which is funded by adult-use marijuana retail taxes, is …
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this …
The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be approved as effective treatment for severe, chronic PTSD in 2023. 67% of participants who …
Widespread anecdotal reports of benefit have led to self-treatment of the symptoms of PTSD with cannabis among Veterans and others; the safety and potential efficacy of such treatments have not previously …
FOR IMMEDIATE RELEASEDecember 7, 2020 Cognitive-behavioral conjoint therapy (CBCT) for posttraumatic stress disorder (PTSD), when combined with MDMA, resulted in significant improvements in PTSD symptoms …
Pilot study explored the application of MDMA-assisted psychotherapy in 18 individuals experiencing moderate to severe anxiety following diagnosis with a life-threatening illness. The primary outcome, change …
